Micro Labs is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $28.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Micro Labs' stage | 2025 brand sales |
|---|---|---|---|---|---|
| Xarelto | Bayer / Johnson & Johnson | Generic | 2025 | FDA-approved 30 Jun 2026 | ≈$5.3B |
| Farxiga | AstraZeneca | Generic | 2026 | FDA-approved 6 Apr 2026 | $8.4B |
| Eliquis | Bristol Myers Squibb / Pfizer | Generic | 2028 | FDA-approved 23 Dec 2019, not marketed | $14.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Micro Labs' share of it.
Micro Labs has FDA approval for Farxiga, Eliquis and Xarelto, with no US launch confirmed. Of the 70 makers we follow, 25 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.